SLC-0111

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H12FN3O3S
Molecular Weight	309.316
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NS(=O)(=O)C1=CC=C(NC(=O)NC2=CC=C(F)C=C2)C=C1

InChI

InChIKey=YJQZNWPYLCNRLP-UHFFFAOYSA-N

InChI=1S/C13H12FN3O3S/c14-9-1-3-10(4-2-9)16-13(18)17-11-5-7-12(8-6-11)21(15,19)20/h1-8H,(H2,15,19,20)(H2,16,17,18)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23208505
Curator's Comment: description was created based on several sources, including https://goo.gl/ifaw1R | https://www.ncbi.nlm.nih.gov/pubmed/26233435 | https://www.ncbi.nlm.nih.gov/pubmed/21145236 | https://www.ncbi.nlm.nih.gov/pubmed/23463940

U-104 is an inhibitor of CA IX that binds only to CA IX under hypoxic conditions in vivo. The binding results in significant inhibition of tumor growth and metastasis formation in both spontaneous and experimental models of metastasis. U-104 reduces the medium acidity by inhibiting the catalytic activity of the CA IX. It binds specifically only to hypoxic cells expressing CA IX.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Carbonic anhydrase IX 35 Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26233435	Inhibitor 8297	45.0 nM [Ki]
Carbonic anhydrase XII 30 Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26233435	Inhibitor 8297	4.5 nM [Ki]
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21145236	Inhibitor 8297	96.0 nM [Ki]
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26233435	Inhibitor 8297	5080.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23208505	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Activation of carbonic anhydrase IX by alternatively spliced tissue factor under late-stage tumor conditions.	2016 Dec	27721473

Patents

Sample Use Guides

In Vivo Use Guide

4T1 cells were implanted orthotopically into Balb/c mice and treatment was initiated after tumors were established.U-104 was solubilized in 55.6% PEG 400, 11.1% ethanol and 33% water at 5 mg/ml, and then administered as oral gavage. In separate experiment MDA-MB-231 LM2-4Lucю cells were implanted into NOD/SCID mice, tumors were established and treatment was initiated. Paclitaxel was administered by i.v. injection and U-104 was provided by intraperitoneal (i.p.) injection according to the dosing schedule.

Route of Administration: Other

In Vitro Use Guide

Parental 4T1 cells were cultured as TSs in hypoxia and subjected to FACS. Viable CD44юCD24_/low or CD44_CD24ю cells were collected. Collected cells were cultured in hypoxia with DMSO or 50 mkM U-104 for 72 h. Cells were fixed and immunostained

Name

Type

Language

SLC-0111

Code

English

4-[[[(4-Fluorophenyl)amino]carbonyl]amino]benzenesulfonamide

Systematic Name

English

U-104

Code

English

U104

Code

English

NSC-213841

Code

English

Benzenesulfonamide, 4-[[[(4-fluorophenyl)amino]carbonyl]amino]-

Systematic Name

English

SLC0111

Code

English

Code System Code Type Description

FDA UNII

ANM9DBL9JT